TP53 and hepatocellular carcinoma: As expected, trametinib treatment had a lower IC50 value in Hep3B than the other HCC and hepatoblastoma cell lines (Fig. 5), suggesting that inhibition of the MAPK pathway might be a potential therapeutic strategy against TP53-null HCCs.